Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2451609rdf:typepubmed:Citationlld:pubmed
pubmed-article:2451609lifeskim:mentionsumls-concept:C0138741lld:lifeskim
pubmed-article:2451609lifeskim:mentionsumls-concept:C0031545lld:lifeskim
pubmed-article:2451609lifeskim:mentionsumls-concept:C0022478lld:lifeskim
pubmed-article:2451609lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:2451609lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:2451609lifeskim:mentionsumls-concept:C0547047lld:lifeskim
pubmed-article:2451609pubmed:issue1lld:pubmed
pubmed-article:2451609pubmed:dateCreated1988-5-13lld:pubmed
pubmed-article:2451609pubmed:abstractTextComplex contact activation systems may have major involvement in side effects of i.v. contrast media. To investigate this, quantitative measurements of several factors (plasma prekallikrein, kallikrein inhibitory activity, haematocrit, alpha-2-macroglobulin, antithrombin III, alpha-1-antitrypsin and beta-thromboglobulin) were made before and after i.v. contrast phlebography in two groups of patients (each containing 21 patients) with no thrombosis, using a high- (meglumine iodamide) and a low-osmolality (ioxaglate) contrast medium. A statistically significant decrease in plasma prekallikrein was observed after the high-osmolality contrast medium, which is a sign of the activation of the kallikrein-kinin system and an indicator of the activation of the intrinsic coagulation. These events may play an important role in the adverse effects of contrast media.lld:pubmed
pubmed-article:2451609pubmed:languageenglld:pubmed
pubmed-article:2451609pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2451609pubmed:citationSubsetIMlld:pubmed
pubmed-article:2451609pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2451609pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2451609pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2451609pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2451609pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2451609pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2451609pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2451609pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2451609pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2451609pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2451609pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2451609pubmed:statusMEDLINElld:pubmed
pubmed-article:2451609pubmed:monthFeblld:pubmed
pubmed-article:2451609pubmed:issn0720-048Xlld:pubmed
pubmed-article:2451609pubmed:authorpubmed-author:VahteraEElld:pubmed
pubmed-article:2451609pubmed:authorpubmed-author:TorstilaIIlld:pubmed
pubmed-article:2451609pubmed:authorpubmed-author:AronenH JHJlld:pubmed
pubmed-article:2451609pubmed:authorpubmed-author:SuorantaH THTlld:pubmed
pubmed-article:2451609pubmed:issnTypePrintlld:pubmed
pubmed-article:2451609pubmed:volume8lld:pubmed
pubmed-article:2451609pubmed:ownerNLMlld:pubmed
pubmed-article:2451609pubmed:authorsCompleteYlld:pubmed
pubmed-article:2451609pubmed:pagination30-3lld:pubmed
pubmed-article:2451609pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2451609pubmed:meshHeadingpubmed-meshheading:2451609-...lld:pubmed
pubmed-article:2451609pubmed:meshHeadingpubmed-meshheading:2451609-...lld:pubmed
pubmed-article:2451609pubmed:meshHeadingpubmed-meshheading:2451609-...lld:pubmed
pubmed-article:2451609pubmed:meshHeadingpubmed-meshheading:2451609-...lld:pubmed
pubmed-article:2451609pubmed:meshHeadingpubmed-meshheading:2451609-...lld:pubmed
pubmed-article:2451609pubmed:meshHeadingpubmed-meshheading:2451609-...lld:pubmed
pubmed-article:2451609pubmed:meshHeadingpubmed-meshheading:2451609-...lld:pubmed
pubmed-article:2451609pubmed:meshHeadingpubmed-meshheading:2451609-...lld:pubmed
pubmed-article:2451609pubmed:meshHeadingpubmed-meshheading:2451609-...lld:pubmed
pubmed-article:2451609pubmed:meshHeadingpubmed-meshheading:2451609-...lld:pubmed
pubmed-article:2451609pubmed:meshHeadingpubmed-meshheading:2451609-...lld:pubmed
pubmed-article:2451609pubmed:meshHeadingpubmed-meshheading:2451609-...lld:pubmed
pubmed-article:2451609pubmed:meshHeadingpubmed-meshheading:2451609-...lld:pubmed
pubmed-article:2451609pubmed:year1988lld:pubmed
pubmed-article:2451609pubmed:articleTitleDecrease of plasma prekallikrein and kallikrein inhibitors during intravenous phlebography.lld:pubmed
pubmed-article:2451609pubmed:affiliationDepartment of Diagnostic Radiology, Helsinki University Central Hospital, Finland.lld:pubmed
pubmed-article:2451609pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2451609pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed